HK1091134A1 - 2-aminoaryloxazole compounds as tyrosine kinase inhibitors - Google Patents
2-aminoaryloxazole compounds as tyrosine kinase inhibitorsInfo
- Publication number
- HK1091134A1 HK1091134A1 HK06111993.8A HK06111993A HK1091134A1 HK 1091134 A1 HK1091134 A1 HK 1091134A1 HK 06111993 A HK06111993 A HK 06111993A HK 1091134 A1 HK1091134 A1 HK 1091134A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- tyrosine kinase
- kinase inhibitors
- compounds
- aminoaryloxazole
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Surgery (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51321403P | 2003-10-23 | 2003-10-23 | |
PCT/IB2004/003698 WO2005040139A2 (en) | 2003-10-23 | 2004-10-22 | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1091134A1 true HK1091134A1 (en) | 2007-01-12 |
Family
ID=42827352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06111993.8A HK1091134A1 (en) | 2003-10-23 | 2006-11-01 | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors |
Country Status (16)
Country | Link |
---|---|
US (2) | US7718676B2 (de) |
EP (1) | EP1684750B1 (de) |
JP (1) | JP4971797B2 (de) |
CN (1) | CN1950347B (de) |
AT (1) | ATE465731T1 (de) |
AU (1) | AU2004283162B2 (de) |
BR (1) | BRPI0415467A (de) |
CA (1) | CA2542909C (de) |
DK (1) | DK1684750T3 (de) |
HK (1) | HK1091134A1 (de) |
HR (1) | HRP20100326T1 (de) |
IL (1) | IL175028A (de) |
NO (1) | NO20062308L (de) |
NZ (1) | NZ546645A (de) |
PL (1) | PL1684750T3 (de) |
WO (1) | WO2005040139A2 (de) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2233686B1 (de) | 2003-05-31 | 2017-09-06 | OneSubsea IP UK Limited | Vorrichtung und Verfahren zur Rückgewinnung von Flüssigkeiten aus einem Bohrloch und/oder zum Einspritzen von Flüssigkeiten in ein Bohrloch |
CA2528438A1 (en) * | 2003-06-03 | 2005-01-06 | Novartis Ag | P-38 inhibitors |
CA2542909C (en) * | 2003-10-23 | 2012-07-10 | Ab Science | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors |
DE602005013496D1 (de) | 2004-02-26 | 2009-05-07 | Cameron Systems Ireland Ltd | Verbindungssystem für unterwasser-strömungsgrenzflächenausrüstung |
WO2005102318A1 (en) * | 2004-04-20 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating hiv related diseases |
US20080146585A1 (en) * | 2004-04-20 | 2008-06-19 | Ab Science | Use Of C-Kit Inhibitors For Treating Inflammatory Muscle Disorders Including Myositis And Muscular Dystrophy |
CA2566104A1 (en) * | 2004-05-18 | 2005-12-01 | Ab Science | Use of mast cells inhibitors for treating patients exposed to chemical or biological weapons |
WO2005115385A1 (en) * | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating acne |
KR20080019578A (ko) * | 2005-04-04 | 2008-03-04 | 에이비 사이언스 | 치환된 옥사졸 유도체 및 이의 티로신 키나제 억제제로서의용도 |
US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
EP1904065A2 (de) * | 2005-07-14 | 2008-04-02 | AB Science | Verwendung von dualen c-kit/fgfr3-hemmern zur behandlung von multiplem myelom |
WO2007076460A2 (en) * | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Substituted thiazole ureas useful as inhibitors of protein kinases |
WO2007124316A1 (en) | 2006-04-20 | 2007-11-01 | Janssen Pharmaceutica N.V. | Heterocyclic compounds as inhibitors of c-fms kinase |
RU2475483C2 (ru) | 2006-04-20 | 2013-02-20 | Янссен Фармацевтика Н.В. | Ингибиторы с-fms киназы |
US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
EP2015748B1 (de) * | 2006-04-20 | 2012-07-04 | Janssen Pharmaceutica NV | Ein C-Kit-Kinase Inhibitor zur Verwendung in der Behandlung von gastrointestinalem Stromatumor oder Mastozytose |
GB0618001D0 (en) | 2006-09-13 | 2006-10-18 | Des Enhanced Recovery Ltd | Method |
US7790756B2 (en) * | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
GB0625191D0 (en) | 2006-12-18 | 2007-01-24 | Des Enhanced Recovery Ltd | Apparatus and method |
GB0625526D0 (en) | 2006-12-18 | 2007-01-31 | Des Enhanced Recovery Ltd | Apparatus and method |
WO2008084103A1 (en) * | 2007-01-12 | 2008-07-17 | Ab Science | Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors |
GB0701426D0 (en) * | 2007-01-25 | 2007-03-07 | Univ Sheffield | Compounds and their use |
GB0709031D0 (en) * | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
FR2928150A1 (fr) * | 2008-02-29 | 2009-09-04 | Vetoquinol Sa Sa | Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens |
EP2145891A1 (de) * | 2008-07-09 | 2010-01-20 | Vetoquinol S.A. | 9-substierte 5-Carboxy-Oxadiazin-Chinolon-Derivate, ihre Herstellung und ihre Anwendung als antibakterielle Mittel |
GB0820819D0 (en) | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
EP2680846A4 (de) * | 2011-03-01 | 2014-08-06 | Npharmakon Llc | Verwendung von n-(4-methoxyphenyl)-1-phenyl-1h-pyrazol-3-amin und verbindungen in zusammenhang damit |
EP2714667B1 (de) | 2011-05-27 | 2020-11-25 | Laxman S. DESAI | Aminooxazolhemmer von cyclinabhängigen kinasen |
RU2612972C2 (ru) * | 2011-07-27 | 2017-03-14 | Аб Сьянс | Селективные ингибиторы протеинкиназ |
GB201202027D0 (en) | 2012-02-06 | 2012-03-21 | Sareum Ltd | Pharmaceutical compounds |
DK2634185T3 (en) | 2012-03-02 | 2016-03-21 | Sareum Ltd | Tyk2 kinase inhibitors |
IN2015DN00659A (de) | 2012-08-07 | 2015-06-26 | Janssen Pharmaceutica Nv | |
JOP20180012A1 (ar) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
US20160175302A1 (en) * | 2014-12-17 | 2016-06-23 | Ab Science | Masitinib for treating gastric cancer |
EP3053920B1 (de) * | 2015-02-05 | 2020-04-08 | AB Science | Verbindungen mit antitumoraktivität |
CA2978518C (en) | 2015-03-27 | 2023-11-21 | Nathanael S. Gray | Inhibitors of cyclin-dependent kinases |
CA2996978A1 (en) * | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
GB201617871D0 (en) | 2016-10-21 | 2016-12-07 | Sareum Limited | Pharmaceutical compounds |
WO2021047677A1 (zh) * | 2019-09-12 | 2021-03-18 | 中国科学院上海药物研究所 | 一类irak4激酶抑制剂及其制备和应用 |
EP4200167A1 (de) * | 2020-08-21 | 2023-06-28 | Pylon Manufacturing Corp. | Scheibenwischerblatt |
CN113185511B (zh) * | 2021-05-24 | 2022-04-26 | 中国医学科学院医药生物技术研究所 | 一种嘧啶类化合物及其制备方法和应用 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3740420A (en) * | 1967-11-28 | 1973-06-19 | Crown Zellerbach Corp | Pharmaceutical compositions with dimethyl sulfoxide |
FR2077803B1 (de) * | 1970-02-16 | 1973-03-16 | Innothera Lab Sa | |
US3743727A (en) * | 1970-11-16 | 1973-07-03 | Crown Zellerbach Corp | Enhancing tissue penetration of certain antimicrobial agents with dimethyl sulfoxide |
US3989816A (en) * | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
US4405616A (en) * | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
US4343940A (en) * | 1979-02-13 | 1982-08-10 | Mead Johnson & Company | Anti-tumor quinazoline compounds |
CA1163561A (en) * | 1979-11-06 | 1984-03-13 | Cyril Boroda | Preparation containing nitroglycerine and optionally other medicaments and preparation thereof |
US4460372A (en) * | 1981-02-17 | 1984-07-17 | Alza Corporation | Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer |
US4379454A (en) * | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
US4411893A (en) * | 1981-08-14 | 1983-10-25 | Minnesota Mining And Manufacturing Company | Topical medicament preparations |
CA1236029A (en) * | 1984-05-14 | 1988-05-03 | Edmund Sandborn | Pharmaceutical solutions comprising dimethyl sulfoxide |
US4615699A (en) * | 1985-05-03 | 1986-10-07 | Alza Corporation | Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes |
US5000775A (en) * | 1985-12-31 | 1991-03-19 | Monsanto Company | 2-amino-4,5-disubstituted-oxazole/thiazole compounds as herbicide antidotes |
JPH0651679B2 (ja) * | 1986-07-21 | 1994-07-06 | 株式会社大塚製薬工場 | p−アミノフェノ−ル誘導体 |
US4868183A (en) * | 1986-07-21 | 1989-09-19 | Otsuka Pharmaceutical Factory, Inc. | N-pyrazinyl substituted P-aminophenols |
US5217999A (en) * | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
WO1991015495A1 (en) | 1990-04-02 | 1991-10-17 | Pfizer Inc. | Benzylphosphonic acid tyrosine kinase inhibitors |
US5302606A (en) * | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
SG64322A1 (en) | 1991-05-10 | 1999-04-27 | Rhone Poulenc Rorer Int | Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
US5714493A (en) * | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
EP0586608A1 (de) | 1991-05-29 | 1994-03-16 | Pfizer Inc. | Tricyclische polyhydroxy tyrosin-kinase-inhibitoren |
US5213453A (en) | 1991-06-28 | 1993-05-25 | Tapmatic Corporation | Cooling systems in tapping attachments suitable for high pressure applications |
GB9121418D0 (en) * | 1991-10-09 | 1991-11-20 | Nader Esfahani Rahim | Imaginograph |
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
CA2140440A1 (en) | 1992-08-06 | 1994-02-17 | Ellen M. Dobrusin | 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties |
US5330992A (en) * | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
US5656643A (en) * | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US5906202A (en) * | 1996-11-21 | 1999-05-25 | Aradigm Corporation | Device and method for directing aerosolized mist to a specific area of the respiratory tract |
EP0949242A4 (de) | 1996-12-24 | 2004-09-08 | Chugai Seiyakukabushiki Kaisha | Aromatische aminderivate mit nos-hemmender wirkung |
JPH10237028A (ja) * | 1996-12-24 | 1998-09-08 | Chugai Pharmaceut Co Ltd | Nos阻害作用を有する芳香族アミン誘導体 |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
JP2002528499A (ja) * | 1998-10-29 | 2002-09-03 | ブリストル−マイヤーズ スクイブ カンパニー | Impdh酵素のインヒビターであるアミノ核誘導化合物 |
US6596747B2 (en) * | 1998-10-29 | 2003-07-22 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus and pharmaceutical compositions comprising same |
WO2000038519A1 (en) | 1998-12-31 | 2000-07-06 | Sugen, Inc. | 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy |
US20020137755A1 (en) * | 2000-12-04 | 2002-09-26 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
EP1471907B1 (de) | 2001-06-29 | 2008-07-16 | AB Science | Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen |
ATE330608T1 (de) | 2001-06-29 | 2006-07-15 | Ab Science | Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen |
ATE343415T1 (de) | 2001-06-29 | 2006-11-15 | Ab Science | Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen |
WO2003002107A2 (en) | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms) |
JP2005500041A (ja) | 2001-06-29 | 2005-01-06 | アブ サイエンス | 強力で選択的かつ非毒性のc−kit阻害剤 |
US20030091974A1 (en) | 2001-06-29 | 2003-05-15 | Alain Moussy | Method for screening compounds capable of depleting mast cells |
WO2003004006A2 (en) | 2001-06-29 | 2003-01-16 | Ab Science | Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis |
CA2452171A1 (en) | 2001-06-29 | 2003-01-09 | Ab Science | Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
US20040266771A1 (en) | 2001-06-29 | 2004-12-30 | Alain Moussy | Use of tyrosine kinase inhibitors for treating bone loss |
PT1401413E (pt) | 2001-06-29 | 2007-02-28 | Ab Science | Uso de inibidores da tirosina cinase para tratar doenças alérgicas |
CA2461181A1 (en) | 2001-09-20 | 2003-05-01 | Ab Science | Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections |
CA2461183A1 (en) | 2001-09-20 | 2003-05-15 | Ab Science | Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases |
CA2461182A1 (en) | 2001-09-20 | 2003-05-01 | Ab Science | Use of tyrosine kinase inhibitors for promoting hair growth |
AU2003216625A1 (en) | 2002-02-27 | 2003-09-09 | Ab Science | Use of tyrosine kinase inhibitors for treating cns disorders |
EP1490067B1 (de) | 2002-02-27 | 2008-09-17 | AB Science | Verwendung von tyrosinkinase-hemmern zur behandlung von erkrankungen im zusammenhang mit substanzgebrauch |
TW200401638A (en) * | 2002-06-20 | 2004-02-01 | Bristol Myers Squibb Co | Heterocyclic inhibitors of kinases |
JP2006503081A (ja) * | 2002-10-10 | 2006-01-26 | スミスクライン ビーチャム コーポレーション | 化学化合物 |
US20080025916A1 (en) | 2003-02-27 | 2008-01-31 | Ab Science | Tailored Treatment Suitable for Different Forms of Mastocytosis |
CA2528438A1 (en) | 2003-06-03 | 2005-01-06 | Novartis Ag | P-38 inhibitors |
CN1829513A (zh) * | 2003-06-03 | 2006-09-06 | 诺瓦提斯公司 | 基于五元杂环的p-38抑制剂 |
CA2542909C (en) * | 2003-10-23 | 2012-07-10 | Ab Science | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors |
-
2004
- 2004-10-22 CA CA2542909A patent/CA2542909C/en not_active Expired - Fee Related
- 2004-10-22 DK DK04791783.6T patent/DK1684750T3/da active
- 2004-10-22 PL PL04791783T patent/PL1684750T3/pl unknown
- 2004-10-22 CN CN2004800371595A patent/CN1950347B/zh not_active Expired - Fee Related
- 2004-10-22 NZ NZ546645A patent/NZ546645A/en not_active IP Right Cessation
- 2004-10-22 JP JP2006536215A patent/JP4971797B2/ja not_active Expired - Fee Related
- 2004-10-22 WO PCT/IB2004/003698 patent/WO2005040139A2/en active Application Filing
- 2004-10-22 AU AU2004283162A patent/AU2004283162B2/en not_active Ceased
- 2004-10-22 AT AT04791783T patent/ATE465731T1/de active
- 2004-10-22 BR BRPI0415467-3A patent/BRPI0415467A/pt not_active IP Right Cessation
- 2004-10-22 EP EP04791783A patent/EP1684750B1/de active Active
- 2004-10-22 US US10/576,267 patent/US7718676B2/en not_active Expired - Fee Related
-
2006
- 2006-04-20 IL IL175028A patent/IL175028A/en not_active IP Right Cessation
- 2006-05-22 NO NO20062308A patent/NO20062308L/no not_active Application Discontinuation
- 2006-11-01 HK HK06111993.8A patent/HK1091134A1/xx not_active IP Right Cessation
-
2010
- 2010-01-11 US US12/654,957 patent/US8110591B2/en not_active Expired - Fee Related
- 2010-06-07 HR HR20100326T patent/HRP20100326T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
NZ546645A (en) | 2010-02-26 |
CN1950347A (zh) | 2007-04-18 |
EP1684750B1 (de) | 2010-04-28 |
CA2542909A1 (en) | 2005-05-06 |
HRP20100326T1 (hr) | 2010-10-31 |
US7718676B2 (en) | 2010-05-18 |
US8110591B2 (en) | 2012-02-07 |
JP2007509130A (ja) | 2007-04-12 |
US20100113471A1 (en) | 2010-05-06 |
JP4971797B2 (ja) | 2012-07-11 |
EP1684750A2 (de) | 2006-08-02 |
ATE465731T1 (de) | 2010-05-15 |
WO2005040139A2 (en) | 2005-05-06 |
CN1950347B (zh) | 2012-04-04 |
DK1684750T3 (da) | 2010-08-09 |
US20070142390A1 (en) | 2007-06-21 |
WO2005040139A3 (en) | 2005-10-13 |
NO20062308L (no) | 2006-05-22 |
WO2005040139A8 (en) | 2006-06-01 |
BRPI0415467A (pt) | 2006-12-19 |
IL175028A (en) | 2011-02-28 |
IL175028A0 (en) | 2006-08-20 |
CA2542909C (en) | 2012-07-10 |
PL1684750T3 (pl) | 2010-10-29 |
AU2004283162B2 (en) | 2011-12-15 |
AU2004283162A1 (en) | 2005-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1091134A1 (en) | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors | |
MXPA05001277A (es) | 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit. | |
UA95071C2 (ru) | Замещенные производные оксазола и их применение как ингибиторов тирозинкиназы | |
NO20063861L (no) | 2-(3-substituert aryl)amin-4-arylthiazoler som tyrosinkinasehemmere | |
MXPA05010711A (es) | Compuestos y composiciones novedosos como inhibidores de proteina-quinasa. | |
CY1110663T1 (el) | 2-αμινοαρυλοξαζολικες ενωσεις ως παρεμποδιστες κινασων της τυροσινης | |
TW200510403A (en) | Cyclic protein tyrosine kinase inhibitors | |
MX2012008083A (es) | Inhibidores de triazol y oxazol quinaza. | |
TW200801008A (en) | Protein kinase inhibitors | |
EP1503757A4 (de) | Tyrosinkinase-hemmer | |
ATE450530T1 (de) | Zusammensetzungen zur verwendung als protein- kinase-inhibitoren | |
EP2609919A3 (de) | c-Met-Modulatoren und Verwendungsverfahren | |
WO2005116025A3 (en) | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | |
ATE548363T1 (de) | 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen | |
NO20072567L (no) | Triazoler nyttige som proteinkinase-inhibitorer | |
WO2006037032A3 (en) | Prodrugs of protein tyrosine kinase inhibitors | |
ZA200609637B (en) | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors | |
CU23680B7 (es) | Derivados de oxazol sustituidos y su uso como inhibidores de tirosina quinasa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20161022 |